WT1 and cancer: In humans, peptide-based vaccines with HLA-A24-restricted WT1235−243 epitopes have been well characterized in the literature to elicit WT1-specific CD8+ T cell responses in adult and children cancer patients with the HLA-A24 allele (52–56).